nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical Universitynefr-57Research ArticleСтатьиСОВРЕМЕННОЕ СОСТОЯНИЕ ВОПРОСА ОБ ИСПОЛЬЗОВАНИИ ЭНТЕРОСОРБЦИИ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕКTHE CURRENT STATE OF THE PROBLEM ABOUT THE USE OF ENTEROSORPTION IN CKDЛукичёвБ. Г.LukichevB. G.noemail@neicon.ruСтрелкоВ. В.StrelkoV. V.noemail@neicon.ruМосикянА. А.MosikyanA. A.noemail@neicon.ruТрихлебВ. А.TrikhlebV. A.noemail@neicon.ruПервый Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаРоссияPavlov First Saint Petersburg State Medical UniversityRussian FederationИнститут сорбции и проблем эндоэкологии НАН УкраиныРоссияInstitute for Sorption and Problems of Endoecology The National Academy of Sciences of UkraineRussian Federation2014011120141864350Copyright © Лукичёв Б.Г., Стрелко В.В., Мосикян А.А., Трихлеб В.А., 20142014Лукичёв Б.Г., Стрелко В.В., Мосикян А.А., Трихлеб В.А.Lukichev B.G., Strelko V.V., Mosikyan A.A., Trikhleb V.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/57

Обсуждаются современные представления об эффективности применения перорального приема сорбентов при лечении хронической болезни почек (ХБП). Проводится сопоставление угля «AST-120» (Япония) с отечественными углями «СКН» и Carbon. Обобщаются данные об эффективности приема углеродных сорбентов для продления до-диализного периода и уменьшения уремической интоксикации.

The modern practice the effectiveness of applying oral sorbents as a treatment of CKD is discussed. Carbo «AST-120» (Japan) is compared with carbo activatus «SCN» and «Carbon» (Russia). The summary of the effectiveness data on taking oral sorbents to extend a before dialysis period and reducing uremic intoxication is provided.

хроническая болезнь почекуглеродные сорбентыchronic kidney diseasecarbon sorbentsReferencesШостка Г.Д., Рябов С.И., Лукичев Б.Г. и др. Пероральные сорбенты в терапии хронической почечной недостаточности. Тер. архив - 1984 - № 7 - с. 58-63Шостка Г.Д., Рябов С.И., Лукичев Б.Г. и др. Пероральные сорбенты в терапии хронической почечной недостаточности. Тер. архив - 1984 - № 7 - с. 58-63Рябов С.И., Цюра В.И., Лукичев Б.Г. и др. Энтеросорбция при экспериментальной острой почечной недостаточности. Урология и нефрология. - 1990 - № 6. - с. 44-49Рябов С.И., Цюра В.И., Лукичев Б.Г. и др. Энтеросорбция при экспериментальной острой почечной недостаточности. Урология и нефрология. - 1990 - № 6. - с. 44-49Лукичев Б.Г., Шостка Г.Д., Стрелко В.В. и др. 10-летний опыт применения энтеросорбентов для лечения хронической почечной недостаточности. Тер.архив - 1992 - № 8 - с. 52-57Лукичев Б.Г., Шостка Г.Д., Стрелко В.В. и др. 10-летний опыт применения энтеросорбентов для лечения хронической почечной недостаточности. Тер.архив - 1992 - № 8 - с. 52-57Hatakeyama S(1), Yamamoto H., Okamoto A., et al. Effect of an Oral Adsorbent, «AST-120», on Dialysis Initiation and Survival in Patients with Chronic Kidney Disease. Int J Nephrol. 2012; 2012: 376128.Hatakeyama S(1), Yamamoto H., Okamoto A., et al. Effect of an Oral Adsorbent, «AST-120», on Dialysis Initiation and Survival in Patients with Chronic Kidney Disease. Int J Nephrol. 2012; 2012: 376128.Sanaka T.(1), Akizawa T., Koide K., Koshikawa S. Clinical analysis of renoprotective responding patients administrated with oral adsorbent in chronic renal failure secondary to chronic glomerulonephritis. Ther Apher Dial. 2003 Apr; 7(2): 269-78.Sanaka T.(1), Akizawa T., Koide K., Koshikawa S. Clinical analysis of renoprotective responding patients administrated with oral adsorbent in chronic renal failure secondary to chronic glomerulonephritis. Ther Apher Dial. 2003 Apr; 7(2): 269-78.Лукичев Б.Г., Панина И.Ю. Прогнозирование эффективности энтеросорбции при хронической почечной недостаточности. Нефрология - 2005 - Т.9 № 1 - с. 8994Лукичев Б.Г., Панина И.Ю. Прогнозирование эффективности энтеросорбции при хронической почечной недостаточности. Нефрология - 2005 - Т.9 № 1 - с. 8994Niwa T.(1), Yazawa T., Ise M., et al. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxylsulfate in serum of experimental uremic rats. Nephron. 1991; 57(1): 84-8Niwa T.(1), Yazawa T., Ise M., et al. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxylsulfate in serum of experimental uremic rats. Nephron. 1991; 57(1): 84-8Niwa T.(1), Miyazaki T., Hashimoto N., et al. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am J Nephrol. 1992; 12(4): 201-6Niwa T.(1), Miyazaki T., Hashimoto N., et al. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am J Nephrol. 1992; 12(4): 201-6Niwa T.(1), Miyazaki T., Tsukushi S., et al. Accumulation of indoxyl-beta-D-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis. Nephron. 1996; 74(1): 72-8.Niwa T.(1), Miyazaki T., Tsukushi S., et al. Accumulation of indoxyl-beta-D-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis. Nephron. 1996; 74(1): 72-8.Kobayashi N.(1), Maeda A., Horikoshi S., et al. Effects of oral adsorbent «AST-120» («Kremezin») on renal function and glomerular injury in early-stage renal failure of subtotal nephrectomized rats. Nephron. 2002 Jul; 91(3): 480-5.Kobayashi N.(1), Maeda A., Horikoshi S., et al. Effects of oral adsorbent «AST-120» («Kremezin») on renal function and glomerular injury in early-stage renal failure of subtotal nephrectomized rats. Nephron. 2002 Jul; 91(3): 480-5.Sanaka T.(1), Sugino N., Teraoka S., Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis. 1988 Aug 12(2): 97-103.Sanaka T.(1), Sugino N., Teraoka S., Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis. 1988 Aug 12(2): 97-103.Koide K.(1), Sano M., Takeda F., et al. A study of oral adsorbent in chronic renal failure. Biomater Artif Cells Immobilization Biotechnol. 1991; 19(1): 147-66.Koide K.(1), Sano M., Takeda F., et al. A study of oral adsorbent in chronic renal failure. Biomater Artif Cells Immobilization Biotechnol. 1991; 19(1): 147-66.Niwa T.(1), Nomura T., Sugiyama S., et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. 1. Kidney Int Suppl. 1997 Nov; 62: S23-8.Niwa T.(1), Nomura T., Sugiyama S., et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. 1. Kidney Int Suppl. 1997 Nov; 62: S23-8.Takahashi N.(1), Kawaguchi T., Suzuki T. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study. Int J Urol. 2005 Jan; 12(1): 7-11.Takahashi N.(1), Kawaguchi T., Suzuki T. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study. Int J Urol. 2005 Jan; 12(1): 7-11.Sanaka T.(1), Akizawa T., Koide K., Koshikawa S. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. Ther Apher Dial. 2004 Jun; 8(3): 232-40.Sanaka T.(1), Akizawa T., Koide K., Koshikawa S. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. Ther Apher Dial. 2004 Jun; 8(3): 232-40.Shoji T.(1), Wada A., Inoue K., et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon «AST-120» in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract. 2007; 105(3): c99-107. Epub 2006 Dec 15.Shoji T.(1), Wada A., Inoue K., et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon «AST-120» in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract. 2007; 105(3): c99-107. Epub 2006 Dec 15.Schulman G.(1), Agarwal R., Acharya M., et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of «AST-120» («Kremezin») in patients with moderate to severe CKD. Am J Kidney Dis. 2006 Apr; 47(4): 565-77.Schulman G.(1), Agarwal R., Acharya M., et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of «AST-120» («Kremezin») in patients with moderate to severe CKD. Am J Kidney Dis. 2006 Apr; 47(4): 565-77.Ueda H.(1), Shibahara N., Takagi S., et al. «AST-120», an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial. 2007 Jun; 11(3): 189-95.Ueda H.(1), Shibahara N., Takagi S., et al. «AST-120», an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial. 2007 Jun; 11(3): 189-95.Ueda H.(1), Shibahara N., Takagi S., et al. «AST-120» treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail. 2008; 30(9): 856-60.Ueda H.(1), Shibahara N., Takagi S., et al. «AST-120» treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail. 2008; 30(9): 856-60.Aoyama I.(1), Miyazaki T., Niwa T. Preventive effects of an oral sorbent on nephropathy in rats. Miner Electrolyte Metab. 1999 Jul-Dec; 25(4-6): 365-72.Aoyama I.(1), Miyazaki T., Niwa T. Preventive effects of an oral sorbent on nephropathy in rats. Miner Electrolyte Metab. 1999 Jul-Dec; 25(4-6): 365-72.Aoyama I.(1), Enomoto A., Niwa T. Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis. Am J Kidney Dis. 2003 Mar; 41(3 Suppl 1): S8-14.Aoyama I.(1), Enomoto A., Niwa T. Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis. Am J Kidney Dis. 2003 Mar; 41(3 Suppl 1): S8-14.Miyazaki T.(1), Aoyama I., Ise M., et al. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant. 2000 Nov; 15(11): 1773-81Miyazaki T.(1), Aoyama I., Ise M., et al. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant. 2000 Nov; 15(11): 1773-81Okada K.(1), Matsumoto K., Takahashi S. Oral adsorbent prevents reduction of anionic sites of the glomerular basement membrane in diabetic nephropathy. Nephron Exp Nephrol. 2005; 99(2): e56-62.Okada K.(1), Matsumoto K., Takahashi S. Oral adsorbent prevents reduction of anionic sites of the glomerular basement membrane in diabetic nephropathy. Nephron Exp Nephrol. 2005; 99(2): e56-62.Okada K.(1), Matsumoto K., Takahashi S. Uremic toxins adsorbed by «AST-120» promote tubular hypertrophy and interstitial fibrosis in nephrectomized rats. Kidney Blood Press Res. 2005; 28(1): 8-13.Okada K.(1), Matsumoto K., Takahashi S. Uremic toxins adsorbed by «AST-120» promote tubular hypertrophy and interstitial fibrosis in nephrectomized rats. Kidney Blood Press Res. 2005; 28(1): 8-13.Nakagawa N.(1), Hasebe N., Sumitomo K., Fujino А. et al. An oral adsorbent, «AST-120», suppresses oxidative stress in uremic rats. Am J Nephrol. 2006; 26(5): 455-61.Nakagawa N.(1), Hasebe N., Sumitomo K., Fujino А. et al. An oral adsorbent, «AST-120», suppresses oxidative stress in uremic rats. Am J Nephrol. 2006; 26(5): 455-61.Fujii H.(1), Nishijima F., Goto S., et al. Oral charcoal adsorbent («AST-120») prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009 Jul; 24(7): 2089-95.Fujii H.(1), Nishijima F., Goto S., et al. Oral charcoal adsorbent («AST-120») prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009 Jul; 24(7): 2089-95.Shimoishi K.(1), Anraku M., Kitamura K., et al. An oral adsorbent, «AST-120» protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res. 2007 Jul; 24(7): 1283-9.Shimoishi K.(1), Anraku M., Kitamura K., et al. An oral adsorbent, «AST-120» protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res. 2007 Jul; 24(7): 1283-9.Taki K.(1), Niwa T. Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease. J Ren Nutr. 2007 Jan; 17(1): 48-52.Taki K.(1), Niwa T. Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease. J Ren Nutr. 2007 Jan; 17(1): 48-52.Niwa T.(1), Tsukushi S., Ise M., et al. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab. 1997; 23(3-6): 179-84.Niwa T.(1), Tsukushi S., Ise M., et al. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab. 1997; 23(3-6): 179-84.Owada A.(1), Nakao M., Koike J., et al. Effects of oral adsorbent «AST-120» on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl. 1997 Dec; 63: S188-90.Owada A.(1), Nakao M., Koike J., et al. Effects of oral adsorbent «AST-120» on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl. 1997 Dec; 63: S188-90.Imai E.(1), Takenaka M., Isaka X. et al. Carbonic adsorbent «AST-120» retards progression of renal failure by additive effect with ACEI and protein restriction diet. Clin Exp Nephrol. 2003 Jun; 7(2): 113-9.Imai E.(1), Takenaka M., Isaka X. et al. Carbonic adsorbent «AST-120» retards progression of renal failure by additive effect with ACEI and protein restriction diet. Clin Exp Nephrol. 2003 Jun; 7(2): 113-9.Okada K.(1), Okawa E., Shibahara H., et al. Combination therapy with angiotensin-converting enzyme inhibitor and oral adsorbent of uremic toxins can delay the appearance of glomerular sclerosis and interstitial fibrosis in established renal failure. Kidney Blood Press Res. 2004; 27(4): 218-25.Okada K.(1), Okawa E., Shibahara H., et al. Combination therapy with angiotensin-converting enzyme inhibitor and oral adsorbent of uremic toxins can delay the appearance of glomerular sclerosis and interstitial fibrosis in established renal failure. Kidney Blood Press Res. 2004; 27(4): 218-25.Sanaka T.(1), Fujimoto K., Niwayama J., et al. Effect of combined treatment of oral sorbent with protein-restricted diet on change of reciprocal creatinine slope in patients with CRF. Am J Kidney Dis. 2003 Mar; 41(3 Suppl 1): S35-7.Sanaka T.(1), Fujimoto K., Niwayama J., et al. Effect of combined treatment of oral sorbent with protein-restricted diet on change of reciprocal creatinine slope in patients with CRF. Am J Kidney Dis. 2003 Mar; 41(3 Suppl 1): S35-7.Yorioka N.(1), Kiribayashi K., Naito T., et al. An oral adsorbent, «AST-120», combined with a low-protein diet and RAS blocker, for chronic kidney disease. J Nephrol. 2008 Mar-Apr; 21(2): 213-20.Yorioka N.(1), Kiribayashi K., Naito T., et al. An oral adsorbent, «AST-120», combined with a low-protein diet and RAS blocker, for chronic kidney disease. J Nephrol. 2008 Mar-Apr; 21(2): 213-20.Kang H.Y.(1), Cho W., Lee S., et al. Estimating the cost savings due to the effect of «Kremezin» in delaying the initiation of dialysis treatments among patients with chronic renal failure. J Prev Med Public Health. 2006 Mar; 39(2): 149-58.Kang H.Y.(1), Cho W., Lee S., et al. Estimating the cost savings due to the effect of «Kremezin» in delaying the initiation of dialysis treatments among patients with chronic renal failure. J Prev Med Public Health. 2006 Mar; 39(2): 149-58.

The authors declare that there are no conflicts of interest present.